Literature DB >> 19234536

Recent advances in MeCP2 structure and function.

Kristopher C Hite1, Valerie H Adams, Jeffrey C Hansen.   

Abstract

Mutations in methyl DNA binding protein 2 (MeCP2) cause the neurodevelopmental disorder Rett syndrome (RTT). The mechanism(s) by which the native MeCP2 protein operates in the cell are not well understood. Historically, MeCP2 has been characterized as a proximal gene silencer with 2 functional domains: a methyl DNA binding domain and a transcription repression domain. However, several lines of new data indicate that MeCP2 structure and function relationships are more complex. In this review, we first discuss recent studies that have advanced understanding of the basic structural biochemistry of MeCP2. This is followed by an analysis of cell-based experiments suggesting MeCP2 is a regulator, rather than a strict silencer, of transcription. The new data establish MeCP2 as a multifunctional nuclear protein, with potentially important roles in chromatin architecture, regulation of RNA splicing, and active transcription. We conclude by discussing clinical correlations between domain-specific mutations and RTT pathology to stress that all structural domains of MeCP2 are required to properly mediate cellular function of the intact protein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234536      PMCID: PMC2874317          DOI: 10.1139/O08-115

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  57 in total

1.  The Ski protein family is required for MeCP2-mediated transcriptional repression.

Authors:  K Kokura; S C Kaul; R Wadhwa; T Nomura; M M Khan; T Shinagawa; T Yasukawa; C Colmenares; S Ishii
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

Review 2.  Flexible nets. The roles of intrinsic disorder in protein interaction networks.

Authors:  A Keith Dunker; Marc S Cortese; Pedro Romero; Lilia M Iakoucheva; Vladimir N Uversky
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

Review 3.  Intrinsic protein disorder, amino acid composition, and histone terminal domains.

Authors:  Jeffrey C Hansen; Xu Lu; Eric D Ross; Robert W Woody
Journal:  J Biol Chem       Date:  2005-11-21       Impact factor: 5.157

4.  Crystal structure of the nucleosome core particle at 2.8 A resolution.

Authors:  K Luger; A W Mäder; R K Richmond; D F Sargent; T J Richmond
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

5.  Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs.

Authors:  R R Meehan; J D Lewis; S McKay; E L Kleiner; A P Bird
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

6.  InterRett--The application of bioinformatics to International Rett syndrome research.

Authors:  H Moore; H Leonard; S Fyfe; N De Klerk; N Leonard
Journal:  Ann Hum Biol       Date:  2005 Mar-Apr       Impact factor: 1.533

Review 7.  MeCP2: the chromatin connection and beyond.

Authors:  Jordanka Zlatanova
Journal:  Biochem Cell Biol       Date:  2005-06       Impact factor: 3.626

8.  Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome.

Authors:  Shin-ichi Horike; Shutao Cai; Masaru Miyano; Jan-Fang Cheng; Terumi Kohwi-Shigematsu
Journal:  Nat Genet       Date:  2004-12-19       Impact factor: 38.330

9.  The solution structure of the domain from MeCP2 that binds to methylated DNA.

Authors:  R I Wakefield; B O Smith; X Nan; A Free; A Soteriou; D Uhrin; A P Bird; P N Barlow
Journal:  J Mol Biol       Date:  1999-09-03       Impact factor: 5.469

10.  Histone H3 and H4 modification profiles in a Rett syndrome mouse model.

Authors:  Rocio G Urdinguio; Irene Pino; Santiago Ropero; Mario F Fraga; Manel Esteller
Journal:  Epigenetics       Date:  2006-12-12       Impact factor: 4.528

View more
  54 in total

Review 1.  Complexities of Rett syndrome and MeCP2.

Authors:  Rodney C Samaco; Jeffrey L Neul
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  The phenotype associated with a large deletion on MECP2.

Authors:  Ami Bebbington; Jenny Downs; Alan Percy; Mercé Pineda; Bruria Ben Zeev; Nadia Bahi-Buisson; Helen Leonard
Journal:  Eur J Hum Genet       Date:  2012-04-04       Impact factor: 4.246

Review 3.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

4.  A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing.

Authors:  Steven W Long; Jenny Y Y Ooi; Peter M Yau; Peter L Jones
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

5.  Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Authors:  Joel M Gottesfeld; Massimo Pandolfo
Journal:  Future Neurol       Date:  2009-11-01

Review 6.  Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin.

Authors:  Jeffrey C Hansen; Rajarshi P Ghosh; Christopher L Woodcock
Journal:  IUBMB Life       Date:  2010-10       Impact factor: 3.885

7.  Regulation of adrenal and ovarian steroidogenesis by miR-132.

Authors:  Zhigang Hu; Wen-Jun Shen; Fredric B Kraemer; Salman Azhar
Journal:  J Mol Endocrinol       Date:  2017-07-20       Impact factor: 5.098

8.  Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression.

Authors:  Yongjun Chen; Bo-Chul Shin; Shanthie Thamotharan; Sherin U Devaskar
Journal:  Endocrinology       Date:  2013-03-14       Impact factor: 4.736

9.  Ischemic preconditioning regulates expression of microRNAs and a predicted target, MeCP2, in mouse cortex.

Authors:  Theresa A Lusardi; Carol D Farr; Craig L Faulkner; Giuseppe Pignataro; Tao Yang; Jingquan Lan; Roger P Simon; Julie A Saugstad
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-16       Impact factor: 6.200

10.  SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.

Authors:  Stephanie Hammerich-Hille; Benny A Kaipparettu; Anna Tsimelzon; Chad J Creighton; Shiming Jiang; Jose M Polo; Ari Melnick; Rene Meyer; Steffi Oesterreich
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.